Phare Bio
Phare Bio is a social venture that leverages AI and deep learning to discover and develop novel antibiotics, addressing the critical threat of antimicrobial resistance (AMR). Founded in 2020, the company operates with a unique social venture model, utilizing donor funding for preclinical development and strategic commercial partnerships for clinical stages. Their AI-driven platform, AIBiotics, screens and designs antibiotic candidates significantly faster and more efficiently than traditional methods. Phare Bio aims to bridge the 'valley of death' in drug development, ensuring that these vital therapies reach patients. They have partnered with the Collins Lab at MIT and the Broad Institute, and have received recognition such as the ARPA-H Award and inclusion in Fast Company's World Changing Ideas list.
Phare Bio
Phare Bio is a social venture that leverages AI and deep learning to discover and develop novel antibiotics, addressing the critical threat of antimicrobial resistance (AMR). Founded in 2020, the company operates with a unique social venture model, utilizing donor funding for preclinical development and strategic commercial partnerships for clinical stages. Their AI-driven platform, AIBiotics, screens and designs antibiotic candidates significantly faster and more efficiently than traditional methods. Phare Bio aims to bridge the 'valley of death' in drug development, ensuring that these vital therapies reach patients. They have partnered with the Collins Lab at MIT and the Broad Institute, and have received recognition such as the ARPA-H Award and inclusion in Fast Company's World Changing Ideas list.